News | August 19, 2009

Interventional Radiology Treatment for Uterine Fibroids Considered Safe Option

August 19, 2009 - Uterine fibroid embolization (UFE), a minimally invasive interventional radiology treatment for women that cuts off blood flow to painful fibroids to kill the tumors, is highlighted as an appropriate treatment for women in a Clinical Therapeutics article in the Aug. 13 issue of the New England Journal of Medicine.

According to Scott C. Goodwin, M.D., FSIR, an interventional radiologist who co-authored the journal article "Uterine Fibroid Embolization," UFE is a safe, effective and minimally invasive option for women to consider.

Interventional radiologists use magnetic resonance imaging (or MRI) to determine if fibroids can be appropriately embolized, detect possible alternate causes for the symptoms, rule out misdiagnosis, identify which treatments are best suited for each patient and avoid ineffective treatments. UFE blocks tiny blood vessels that feed fibroids, causing the tumor(s) to die and symptoms to subside. An interventional radiologist uses imaging to guide a thin catheter to the uterine artery to treat the source of the disease internally, avoiding open surgery. The procedure offers less risk, less pain and a shorter recovery time compared to open surgery.

Goodwin noted that interventional radiologists can provide a second opinion and assess whether UFE is a treatment option.

Reference: "Uterine Fibroid Embolization," appears in the Aug. 13 issue of the New England Journal of Medicine, was co-written by Scott C. Goodwin, M.D., FSIR, professor and chair of radiological sciences at the University of California at Irvine, and James B. Spies, M.D., M.P.H., FSIR, professor of radiology and chair of the radiology department at Georgetown University Medical Center in Washington, D.C. Goodwin and Spies are SIR members; Goodwin is currently the SIR treasurer, and Spies is immediate past chair of SIR Foundation.

For more information: www.sirweb.org/

Related Content

Researchers developed a deep learning model that identifies imaging biomarkers to predict a patient’s risk for developing breast cancer

A deep learning model was developed that combined imaging and traditional risk factors.

News | Mammography | November 30, 2020
November 30, 2020 — Researchers at Massachusetts General Hospi...
ProFound AI for DBT offers superior clinical performance when compared to other commercially available breast AI systems
News | Breast Imaging | November 24, 2020
November 24, 2020 — iCAD reported that over 1,000 licenses have been sold as part of...
Densitas Inc., a global provider of A.I. technologies for digital mammography and breast screening, announced its partnership with Mammography Educators to offer the first artificial intelligence powered telehealth technologist training platform to support business continuity in mammography facilities.
News | Mammography | November 20, 2020
November 20, 2020 — Densitas Inc., a global provider of A.I.
Radiologists around the world will have access to a first-of-its-kind online breast density training tool designed to improve radiologists' ability to correctly identify women's breast density categories to comply with the Breast Imaging-Reporting and Data System (BI-RADS), thanks to a collaboration between DetectED-X and Volpara Health. 
News | Breast Density | November 19, 2020
November 19, 2020 — Radiologists around the world will have access to a first-of-its-kind online...
Reduces the complexity of reporting for screening and diagnostic MRI eams to deliver time-saving and patient safety benefits
News | MRI Breast | November 18, 2020
November 18, 2020 — ...
An interview with Professor Christiane Kuhl, M.D., director of radiology, University Hospital Aachen, Germany, on the effects on breast imaging in the COVID-19 era

Getty Images

Feature | Breast Imaging | November 12, 2020 | By Dave Fornell
The pandemic forced many elective procedures, including most areas of...
Images in a 55-year-old woman with a spiculated mass localized in the upper central quadrant (arrow in A, B, D, and E) of right breast detected with digital breast tomosynthesis (DBT) plus synthetic mammography (SM). Breast density was classified as category C with the Breast Imaging Reporting and Data System. Mass was invasive ductal carcinoma, stage I, and was estrogen and progesterone receptor positive and human epidermal growth factor receptor 2 negative. A, Image from SM in craniocaudal view. B, Single

Images in a 55-year-old woman with a spiculated mass localized in the upper central quadrant (arrow in A, B, D, and E) of right breast detected with digital breast tomosynthesis (DBT) plus synthetic mammography (SM). Breast density was classified as category C with the Breast Imaging Reporting and Data System. Mass was invasive ductal carcinoma, stage I, and was estrogen and progesterone receptor positive and human epidermal growth factor receptor 2 negative. A, Image from SM in craniocaudal view. B, Single-slice DBT image in craniocaudal view. C, Magnification of the lesion depicted in B. D, Image from SM in mediolateral oblique view. E, Single-slice DBT image in mediolateral oblique view. F, Magnification of the lesion depicted in E. Images courtesy of Radiological Society of North America

News | Breast Imaging | November 11, 2020
November 11, 2020 — ...
Hologic, Inc. announced innovative updates to its Unifi Analytics platform, a breakthrough business intelligence tool that provides mammography centers insights into technologist performance, proactive device maintenance, and business considerations.
News | Mammography | November 10, 2020
November 10, 2020 — Hologic, Inc.